Bausch Health Americas
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch Health Americas sits in the top decile of US sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count).
Bausch Health Americas: 168 sponsored US clinical trials, 6 recruiting.
Bausch Health Americas sponsors 168 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 144 completed. 86 of these trials are in Phase 3-4 (later-stage) and 68 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 6 trials.
Top-decile sponsor footprint
Bausch Health Americas ranks in the top decile of sponsors by registered trial count (#172 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
144 of 157 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
168 total, page 4 of 4
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
NCT00093093
Open-Label Treatment Extension of Protocol MNTX 302
NCT01367613
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function
NCT01367509
Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone in Volunteers With Impaired Hepatic Function
NCT01367522
Pharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
NCT01366352
Study of Methylnaltrexone (MNTX) for the Relief of Constipation
NCT00402038
Tolerance and Pharmacokinetics Study of MNTX Tablets
NCT01366339
Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative Ileus
NCT01367548
A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients
NCT00401362
Open-Label Treatment Extension of Protocol MNTX 301
NCT01367600
Compassionate Use Study of Methylnaltrexone
NCT01368562
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
NCT01367561
Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous Dose
NCT01367496
Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill
NCT00045799
Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone
NCT01367587
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
NCT01367574
A Study Comparing the Effectiveness and Safety of Varying Dose Strengths (100, 200, 300 and 400 mg) of Extended-release Tramadol HCl With Placebo for the Treatment of Osteoarthritis(OA) of the Knee and/or Hip
NCT00325858
A One-year, Open-label Study to Assess the Safety and Effectiveness of Extended Release Tramadol HCl in the Treatment of Chronic, Non-malignant Pain.
NCT00347685
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 37 |
| Phase 3 | 68 |
| Phase 4 | 18 |
What is open in the Bausch Health Americas pipeline
6 recruiting of 168 indexed (4% open); 144 completed (86%).
Phase mix: 86 late (III/IV) vs 68 early (I/II) (balanced across stages).
Top condition: Acne Vulgaris (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch Health Americas: open-pipeline peers nationwide
Peers matched on 168 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bausch Health Americas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 168 trials (± recruiting share)
- Astellas Pharma Global Development · 168 trials · 11% recruiting
- Seattle Children's Hospital · 168 trials · 17% recruiting
- Sumitomo Pharma America · 168 trials · 4% recruiting
- University of New Mexico · 168 trials · 1% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Bayer · 4% recruiting · 591 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
Related
What to do with this Bausch Health Americas page
168 registered trials is a research-attention snapshot, not an endorsement of Bausch Health Americas or any single study.
- 6 of Bausch Health Americas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Bausch Health Americas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bausch Health Americas pipeline card: 168 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.